TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05549180
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
Study: NCT05549180
Drug: Dovato 50Mg-300Mg Tablet + Biktarvy placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
Study: NCT06710379
Drug: ADRX-0405
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody Drug Conjugate targeting STEAP1
Study: NCT04934527
Drug: Cytotect
Approvals — FDA: no, EMA: no, PMDA: no
Description: The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
Study: NCT06710327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
Study: NCT06708624
Drug: FYB201 0.5 mg (0.05 mL of 10 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVT administration of FYB201 in a PFS
Study: NCT04883619
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
Study: NCT06710756
Drug: [203Pb]Pb-PSV359
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
Study: NCT06710756
Drug: [212Pb]Pb-PSV359
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.
Study: NCT06049082
Drug: KB408 (Nebulization)
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
Study: NCT05191563
Drug: HCP1904-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05191563
Drug: RLD2006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05191563
Drug: RLD2001-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period.
Study: NCT05883241
Drug: 2.5% Diclofenac Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pain relief-gel worn during treatment via SAM patch.
Study: NCT05367492
Drug: Double Blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Study: NCT06159725
Drug: CMTX-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
Study: NCT06159725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
Study: NCT06132841
Drug: AZD6234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive repeated doses of AZD6234 as a solution via SC
Study: NCT06132841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching volumes of the placebo as a solution via SC
Study: NCT05237388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib placebo pill
Study: NCT03867851
Drug: IBsolvMIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug IBsolvMIR
Study: NCT03867851
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinical praxis
Study: NCT04817618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study: NCT05824312
Drug: Tyrosine kinase inhibitor drugs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
Study: NCT05727618
Drug: Pituitrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
Study: NCT05727618
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of normal saline at the same dose and speed
Study: NCT05306379
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose 40 mg
Study: NCT06323928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Lu AG09222 will be administered by SC injection.
Study: NCT05929599
Drug: 0.9% NaCl physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT05737121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo for VNX001
Study: NCT05737121
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized heparin sodium
Study: NCT05406362
Drug: VAD044 Part II
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules to be taken once daily for 12 months
Study: NCT05227742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive inert placebo once per week for 5 weeks.
Study: NCT05657925
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be identical in appearance to the active treatment pill
Study: NCT06467942
Drug: Chinese medicine and Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined drug group
Study: NCT04584125
Drug: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light
Approvals — FDA: no, EMA: no, PMDA: no
Description: A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
Study: NCT04584125
Drug: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Approvals — FDA: no, EMA: no, PMDA: no
Description: The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
Study: NCT04790240
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
Study: NCT05974748
Drug: Propolis 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
Study: NCT06150378
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that receive an injection with corticosteroid
Study: NCT05730283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention
Study: NCT05707936
Drug: Heparin Flush (1000 USP, 10ml)
Normalized name: heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin Flush (1000 USP, 10ml)
Study: NCT06482593
Drug: Zinc-Oxide Eugenol Sealer
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
Study: NCT06482593
Drug: Bio-C Sealer
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
Study: NCT06428682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
Study: NCT03532958
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose volume consistent with weight-based dosing of BNZ-1
Study: NCT04940767
Drug: Amzeeq 4% Topical Foam
Normalized name: Amzeeq 4% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
Study: NCT04767620
Drug: Rugdenzengsheng No. 1 prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
Study: NCT05055128
Drug: X842
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'X842'. Drug abbreviations can vary and may not be standardized, so without more context about the specific clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive X842 tablets.
Study: NCT06191523
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
Study: NCT04483973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo containing excipients
Study: NCT04935359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water (D5W) solution for infusion
Study: NCT06088290
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short intravenous push or bolus (according to label)
Study: NCT05870319
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion (Q2W)
Study: NCT05246670
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06205823
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy
Study: NCT06126042
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRL_AB, Pre Filled Syringe; Solution for injection
Study: NCT06126042
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
Study: NCT06126042
Drug: Reference Medicinal Product
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
Study: NCT04977674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with placebo 45 min before the ketamine infusion.
Study: NCT06153355
Drug: LY3839840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06153355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05715125
Drug: Dose B VTX958
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B VTX958
Study: NCT05715125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06206421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06751485
Drug: JSKN003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT06751485
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05232825
Drug: Methylprednisolone IV
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
Study: NCT06477692
Drug: ENI using IMRT with or without chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
Study: NCT05051735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04773093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
Study: NCT05873699
Drug: Hyperpolarized 13-C-pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by Injection
Study: NCT05043675
Drug: [18F]APN-1607
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study: NCT05933824
Drug: LP-98 injection
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Study: NCT06112548
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml of 30mg/ml ketorolac intraoperative periarticular injection
Study: NCT06112548
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
Study: NCT06112548
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketorolac {Toradol} introduced every 12 hours after surgery.
Study: NCT05885854
Drug: XTR003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes.
Study: NCT05098704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daily during 24 months
Study: NCT06681688
Drug: Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)
Study: NCT06680440
Drug: ASC30
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, QD
Study: NCT06680258
Drug: TPST-1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
Study: NCT05065528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
Study: NCT05264727
Drug: Clinisol 15%
Normalized name: CLINISOL 15% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
Study: NCT05901311
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05901311
Drug: [¹⁴C]-LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05901311
Drug: [¹⁴C]-LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT06538207
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06125054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo (0.9% saline solution i.v. over 40 minutes)
Study: NCT05638776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplantation of Placebo
Study: NCT05139082
Drug: TQB3616 capsules＋ TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study: NCT04798638
Drug: TY-9591 Tablets after a High-fat Meal - Arm1
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT04798638
Drug: TY-9591 Tablets after a High-fat Meal - Arm2
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT05515471
Drug: SHR8058 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8058 eye drops
Study: NCT05515471
Drug: saline eye drops.
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline eye drops.
Study: NCT05493332
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
Study: NCT05493332
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
Study: NCT05559398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
Study: NCT06556966
Drug: LY03020
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03020 for one single dose
Study: NCT06556966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for one single dose
Study: NCT05332730
Drug: BAT2506 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, subcutaneous administration
Study: NCT05332730
Drug: Simponi® (EU commercially available product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, subcutaneous administration
Study: NCT05332730
Drug: Simponi® (US commercially available product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, subcutaneous administration
Study: NCT05842733
Drug: Naldebain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
Study: NCT05842733
Drug: Naldebain + SafeTynadol
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
Study: NCT06529718
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks